Orvosi hetilap · 2014
[Evaluation of the DIABOBHU Observational Study].
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gaál Zsolt, Papp Zsuzsanna, Bakó Barnabás
Аннотация
INTRODUCTION: The authors present and analyze the outcome of DIABOBHU observational study. The work was carried out in Hungarian type 2 diabetic patients whose treatment was insufficient with oral antidiabetic agents.
AIM: The safety and efficacy of glargine insulin added to oral antidiabetic therapy treatment was evaluated.
METHOD: Between 2008 and 2011 3955 patients were enrolled. After proper education, patients titrated the insulin dosage under self-monitoring with the help of their attending physicians. During the 26-week study period 3 visits were included. The primary endpoint was the change of HbA1c. The secondary endpoints were fasting glucose levels, dose of insulin, body weight and body mass index, satisfaction of the patients with the treatment and the incidence of hypoglycemic events.
RESULTS: During the study mean HbA1c decreased from 8.94% to 7.31%. Most patients achieved the glycemic goals with very low frequency of hypoglycemia. The patients did not gain weight and were satisfied with their treatment.
CONCLUSIONS: The authors emphasize that this treatment based on an analogue basal insulin should be considered as an effective and safe therapy.
AIM: The safety and efficacy of glargine insulin added to oral antidiabetic therapy treatment was evaluated.
METHOD: Between 2008 and 2011 3955 patients were enrolled. After proper education, patients titrated the insulin dosage under self-monitoring with the help of their attending physicians. During the 26-week study period 3 visits were included. The primary endpoint was the change of HbA1c. The secondary endpoints were fasting glucose levels, dose of insulin, body weight and body mass index, satisfaction of the patients with the treatment and the incidence of hypoglycemic events.
RESULTS: During the study mean HbA1c decreased from 8.94% to 7.31%. Most patients achieved the glycemic goals with very low frequency of hypoglycemia. The patients did not gain weight and were satisfied with their treatment.
CONCLUSIONS: The authors emphasize that this treatment based on an analogue basal insulin should be considered as an effective and safe therapy.